A comprehensive study of safety evaluation for novel bispecific antibodies combined with chemotherapy in cancer.

Lin, Guo; Sun, Xu; Kang, Kai; Zhao, Ailin; Wu, Yijun

Lin, Guo; Sun, Xu; Kang, Kai; Zhao, Ailin; Wu, Yijun.

Affiliation

Lin G; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University.
Sun X; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University.
Kang K; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Zhao A; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University.
Wu Y; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University.

Int J Surg ; 110(8): 5312-5316, 2024 Aug 01.

Article de En | MEDLINE | ID: mdl-38759680

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Anticorps bispécifiques / Tumeurs Limites: Humans Langue: En Journal: Int J Surg Année: 2024 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google